[1]
Lu J-M, Zhou H-G. Evaluation on behaviors and neuron morphology of Parkinson’s disease rat model. Zhongguo Linchuang Kangfu 2004; 8: 180-3182.
[2]
Blesa J, Phani S, Jackson-Lewis V, Przedborski S. Classic and new animal models of Parkinson’s disease. J Biomed Biotechnol 2012; 2012: 845618.
[http://dx.doi.org/10.1155/2012/845618] [PMID: 22536024]
[http://dx.doi.org/10.1155/2012/845618] [PMID: 22536024]
[3]
Meireles J, Massano J. Cognitive impairment and dementia in Parkinson’s disease: Clinical features, diagnosis, and management. Front Neurol 2012; 3: 88.
[http://dx.doi.org/10.3389/fneur.2012.00088] [PMID: 22654785]
[http://dx.doi.org/10.3389/fneur.2012.00088] [PMID: 22654785]
[4]
Wolters EC, van Laar T, Berendse HW. Parkinsonism and related disorders. 3rd ed. Amsterdam: VU University Press 2010.
[5]
Pfeiffer RF. Gastrointestinal dysfunction in Parkinson’s disease. Parkinsonism Relat Disord 2011; 17(1): 10-5.
[http://dx.doi.org/10.1016/j.parkreldis.2010.08.003] [PMID: 20829091]
[http://dx.doi.org/10.1016/j.parkreldis.2010.08.003] [PMID: 20829091]
[6]
Rodriguez-Oroz MC, Jahanshahi M, Krack P, et al. Initial clinical manifestations of Parkinson’s disease: Features and pathophysiological mechanisms. Lancet Neurol 2009; 8(12): 1128-39.
[http://dx.doi.org/10.1016/S1474-4422(09)70293-5] [PMID: 19909911]
[http://dx.doi.org/10.1016/S1474-4422(09)70293-5] [PMID: 19909911]
[7]
Wolters EC, Francot C, Bergmans P, et al. Preclinical (premotor) Parkinson’s disease. J Neurol 2000; 247(Suppl. 2): II103-9.
[PMID: 10991655]
[PMID: 10991655]
[8]
Wolters ECh, Braak H. Parkinson’s disease: Premotor clinico-pathological correlations. J Neural Transm Suppl 2006; 70(70): 309-19.
[PMID: 17017546]
[PMID: 17017546]
[9]
Zlotnik Y, Balash Y, Korczyn AD, Giladi N, Gurevich T. Disorders of the oral cavity in Parkinson’s disease and parkinsonian syndromes. Parkinsons Dis 2015; 2015: 379482.
[http://dx.doi.org/10.1155/2015/379482] [PMID: 25685594]
[http://dx.doi.org/10.1155/2015/379482] [PMID: 25685594]
[10]
Okyere SK, Zeng C, Yue D, Hu Y. Neurotoxic mechanism and shortcomings of MPTP, 6-OHDA, rotenone and paraquat-induced Parkinson’s disease animal models. Venoms Toxins 2021; 1: 27.
[http://dx.doi.org/10.2174/2666121701999201104163407]
[http://dx.doi.org/10.2174/2666121701999201104163407]
[11]
De Miranda BR, Greenamyre JT, Rocha EM, Castro S, Greenamyre JT. Response to rotenone and Parkinson’s Disease; reduced sensitivity in females. Toxicol Sci 2019; 170(2): 563.
[http://dx.doi.org/10.1093/toxsci/kfz127] [PMID: 31161199]
[http://dx.doi.org/10.1093/toxsci/kfz127] [PMID: 31161199]
[12]
De Miranda BR, Fazzari M, Rocha EM, Castro S, Greenamyre JT. Sex differences in rotenone sensitivity reflect the male-to-female ratio in human Parkinson’s Disease incidence. Toxicol Sci 2019; 170(1): 133-43.
[http://dx.doi.org/10.1093/toxsci/kfz082] [PMID: 30907971]
[http://dx.doi.org/10.1093/toxsci/kfz082] [PMID: 30907971]
[13]
Azmy MS, Menze ET, El-Naga RN, Tadros MG. Neuroprotective effects of Filgrastim in rotenone-induced Parkinson’s Disease in rats: Insights into its anti-Inflammatory, neurotrophic, and antiapoptotic effects. Mol Neurobiol 2018; 55(8): 6572-88.
[http://dx.doi.org/10.1007/s12035-017-0855-1] [PMID: 29327204]
[http://dx.doi.org/10.1007/s12035-017-0855-1] [PMID: 29327204]
[14]
He X, Yang S, Zhang R, et al. Smilagenin protects dopaminergic neurons in chronic MPTP/Probenecid-Lesioned Parkinson’s Disease models. Front Cell Neurosci 2019; 13: 18.
[http://dx.doi.org/10.3389/fncel.2019.00018] [PMID: 30804756]
[http://dx.doi.org/10.3389/fncel.2019.00018] [PMID: 30804756]
[15]
Hu M, Li F, Wang W. Vitexin protects dopaminergic neurons in MPTP-induced Parkinson’s disease through PI3K/Akt signaling pathway. Drug Des Devel Ther 2018; 12: 565-73.
[http://dx.doi.org/10.2147/DDDT.S156920] [PMID: 29588573]
[http://dx.doi.org/10.2147/DDDT.S156920] [PMID: 29588573]
[16]
Wei R, Rong C, Xie Q, et al. Neuroprotective effect of optimized Yinxieling formula in 6- OHDA-Induced chronic model of Parkinson’s Disease through the inflammation pathway. Evid Based Complement Alternat Med 2019; 2019: 2529641.
[http://dx.doi.org/10.1155/2019/2529641] [PMID: 31929812]
[http://dx.doi.org/10.1155/2019/2529641] [PMID: 31929812]
[17]
Voronin MV, Kadnikov IA, Voronkov DN, Seredenin SB. Chaperone Sigma1R mediates the neuroprotective action of afobazole in the 6-OHDA model of Parkinson’s disease. Sci Rep 2019; 9(1): 17020.
[http://dx.doi.org/10.1038/s41598-019-53413-w] [PMID: 31745133]
[http://dx.doi.org/10.1038/s41598-019-53413-w] [PMID: 31745133]
[18]
Vieira JCF, Bassani TB, Santiago RM. de O Guaita, G.; Zanoveli, J.M.; da Cunha, C.; Vital, M.A.B.F. Anxiety-like behavior induced by 6-OHDA animal model of Parkinson’s disease may be related to a dysregulation of neurotransmitter systems in brain areas related to anxiety. Behav Brain Res 2019; 371: 11198.
[http://dx.doi.org/10.1016/j.bbr.2019.111981]
[http://dx.doi.org/10.1016/j.bbr.2019.111981]
[19]
Kurnik M, Gil K, Gajda M, Thor P, Bugajski A. Neuropathic alterations of the myenteric plexus neurons following subacute intraperitoneal administration of salsolinol. Folia Histochem Cytobiol 2015; 53(1): 49-61.
[http://dx.doi.org/10.5603/FHC.a2015.0010] [PMID: 25815627]
[http://dx.doi.org/10.5603/FHC.a2015.0010] [PMID: 25815627]
[20]
Thiruchelvam M. Paraquat and Parkinson's disease, always follow the label instructions when using paraquat: Paraquat Information Center. Available from: https://paraquat.com/en/safety/safety-humans/paraquatand-parkinsons-disease (Accessed March 17, 2020).
[21]
Dawson TM, Ko HS, Dawson VL. Genetic animal models of Parkinson’s disease. Neuron 2010; 66(5): 646-61.
[http://dx.doi.org/10.1016/j.neuron.2010.04.034] [PMID: 20547124]
[http://dx.doi.org/10.1016/j.neuron.2010.04.034] [PMID: 20547124]
[22]
Chaudhuri KR, Yates L, Martinez-Martin P. The non-motor symptom complex of Parkinson’s disease: A comprehensive assessment is essential. Curr Neurol Neurosci Rep 2005; 5(4): 275-83.
[http://dx.doi.org/10.1007/s11910-005-0072-6] [PMID: 15987611]
[http://dx.doi.org/10.1007/s11910-005-0072-6] [PMID: 15987611]
[23]
Gallagher DA, Lees AJ, Schrag A. What are the most important nonmotor symptoms in patients with Parkinson’s disease and are we missing them? Mov Disord 2010; 25(15): 2493-500.
[http://dx.doi.org/10.1002/mds.23394] [PMID: 20922807]
[http://dx.doi.org/10.1002/mds.23394] [PMID: 20922807]
[24]
Kurnik-Łucka M, Bugajski A, Gil K. Modifications of neurotoxin-based animal models of the non-motor complications in Parkinson’s disease in terms of drug development. Pharmacol Drug Dev Ther 2016; 1: 1-6.
[http://dx.doi.org/10.15761/PDDT.1000105]
[http://dx.doi.org/10.15761/PDDT.1000105]
[25]
Guo XX, Wang Y, Wang K, Ji BP, Zhou F. Stability of a type 2 diabetes rat model induced by high-fat diet feeding with low-dose streptozotocin injection. J Zhejiang Univ Sci B 2018; 19(7): 559-69.
[http://dx.doi.org/10.1631/jzus.B1700254] [PMID: 29971994]
[http://dx.doi.org/10.1631/jzus.B1700254] [PMID: 29971994]
[26]
Hyoju SK, Adriaansens C, Wienholts K, et al. Low-fat/high-fibre diet prehabilitation improves anastomotic healing via the microbiome: An experimental model. Br J Surg 2020; 107(6): 743-55.
[http://dx.doi.org/10.1002/bjs.11388] [PMID: 31879948]
[http://dx.doi.org/10.1002/bjs.11388] [PMID: 31879948]
[27]
Staudacher HM, Lomer MCE, Farquharson FM, et al. A diet low in FODMAPs reduces symptoms in patients with Irritable Bowel Syndrome and a probiotic restores Bifidobacterium species: A randomized controlled trial. Gastroenterology 2017; 153(4): 936-47.
[http://dx.doi.org/10.1053/j.gastro.2017.06.010] [PMID: 28625832]
[http://dx.doi.org/10.1053/j.gastro.2017.06.010] [PMID: 28625832]
Article Metrics
7
1